ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,851.70
-0.15%
S&P ASX All Technology
3,077.90
0.70%
Brent Oil
82.79
-0.89%
US Dollar vs AUD
1.50032
0.10%
Bitcoin
69,906.82
-2.16%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vaccitech PLC (VACC)

  7. Vaccitech PLC (VACC) News

VACC

Vaccitech (VACC)

Vaccitech PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VACC
DateTimeSourceHeadlineSymbolCompany
08/11/202301:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VACCVaccitech PLC
21/06/202321:30GlobeNewswire Inc.Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal AntibodyNASDAQ:VACCVaccitech PLC
14/11/202222:30TipRanksAnalysts Are Bullish on These Healthcare Stocks: RAPT Therapeutics (RAPT), Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
08/11/202222:30TipRanksAnalysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Apellis Pharmaceuticals (APLS)NASDAQ:VACCVaccitech PLC
01/11/202221:25TipRanksH.C. Wainwright Reaffirms Their Buy Rating on Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
31/10/202223:00GlobeNewswire Inc.Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV PatientsNASDAQ:VACCVaccitech PLC
04/10/202207:30GlobeNewswire Inc.Vaccitech to Present at Upcoming October Investor & Scientific ConferencesNASDAQ:VACCVaccitech PLC
08/09/202206:01GlobeNewswire Inc.Vaccitech to Present at Upcoming September Investors ConferencesNASDAQ:VACCVaccitech PLC
11/08/202220:25TipRanksH.C. Wainwright Reaffirms Their Buy Rating on Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
10/08/202206:15GlobeNewswire Inc.Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsNASDAQ:VACCVaccitech PLC
08/07/202206:15GlobeNewswire Inc.Vaccitech to Present at the William Blair Biotech Focus Conference 2022NASDAQ:VACCVaccitech PLC
23/06/202220:16TipRanksH.C. Wainwright Reaffirms Their Buy Rating on Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
22/06/202220:00GlobeNewswire Inc.Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1NASDAQ:VACCVaccitech PLC
07/06/202222:05TipRanksAnalysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Ayala Pharmaceuticals (AYLA) and Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
07/06/202206:15GlobeNewswire Inc.Vaccitech to Present at the Jefferies Healthcare ConferenceNASDAQ:VACCVaccitech PLC
06/06/202221:30GlobeNewswire Inc.Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B VirusNASDAQ:VACCVaccitech PLC
21/05/202201:30GlobeNewswire Inc.Vaccitech to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:VACCVaccitech PLC
18/05/202202:35TipRanksWall Street Analysts Are Bullish on Top Healthcare PicksNASDAQ:VACCVaccitech PLC
13/05/202202:10TipRanksAnalysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
12/05/202206:15GlobeNewswire Inc.Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsNASDAQ:VACCVaccitech PLC
07/04/202220:25TipRanksVaccitech Plc (VACC) Gets a Buy Rating from H.C. WainwrightNASDAQ:VACCVaccitech PLC
07/04/202206:15GlobeNewswire Inc.Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®NASDAQ:VACCVaccitech PLC
28/03/202221:25TipRanksWall Street Analysts Are Bullish on Top Healthcare PicksNASDAQ:VACCVaccitech PLC
25/03/202222:15GlobeNewswire Inc.Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate DevelopmentsNASDAQ:VACCVaccitech PLC
08/03/202200:00GlobeNewswire Inc.Vaccitech to Present at the Barclays Global Healthcare Conference 2022NASDAQ:VACCVaccitech PLC
19/01/202222:22TipRanksVaccitech Plc (VACC) Gets a Buy Rating from H.C. WainwrightNASDAQ:VACCVaccitech PLC
18/01/202219:00GlobeNewswire Inc.Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy VaccineNASDAQ:VACCVaccitech PLC
14/01/202208:34GlobeNewswire Inc.Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics LandscapeNASDAQ:VACCVaccitech PLC
15/12/202122:25TipRanksAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Allogene Therapeutics (ALLO) and Vaccitech Plc (VACC)NASDAQ:VACCVaccitech PLC
14/12/202108:05GlobeNewswire Inc.Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccinesNASDAQ:VACCVaccitech PLC
 Showing the most relevant articles for your search:NASDAQ:VACC

Your Recent History

ASX
XJO
S&P ASX 200
ASX
WPL
Woodside Petroleum
NASDAQ
GOOGL
Alphabet
ASX
CBA
Commonwealth Bank Of Aus...
ASX
RIO
Rio Tinto
SPI
SP500
S&P 500
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
COIN
ETHUSD
Ethereum
ASX
FMG
Fortescue
NYSE
JPM
JP Morgan Chase
FX
AUDJPY
AUD vs Yen
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
ASX
ANZ
Australia And New Zealan...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved